| خلاصه مقاله | Background: Osteoarthritis (OA) is one of the most prevalent degenerative joint diseases. According to the World Health Organization, approximately 9.6% of men and 18.0% of women aged over 60 have symptomatic OA. This study aimed to measure the serum levels of melatonin, 8-hydroxy-2-deoxy guanosine, and vitamin D in patients with OA. Based on the role of melatonin, we assumed that melatonin might be involved in the decrease of DNA damage and have a role in preventing OA.
Materials and Methods: This study enrolled 47 patients with OA and 40 healthy controls. Serum levels of melatonin and 8-hydroxy-2-deoxy guanosine (8-OH-dG) were assessed. Also, serum levels of bone turnover biomarkers such as calcium, phosphorus, vitamin D, and alkaline phosphatase (ALP) were measured in OA patients and controls.
Results: The serum level of melatonin was significantly lower in OA patients than the controls (6.18±2.25 vs. 11.57±3.87 pg/mL, P< 0.05). In contrast, the serum level of 8-OH-dG was significantly increased in OA patients compared to controls (65.21±16.12 vs. 22.51±5.3 ng/dL, P< 0.001). There was a negative correlation between serum melatonin and 8-OHdG levels in OA patients (P< 0.05). There was a positive correlation between serum melatonin and vitamin D levels in OA patients (P< 0.05). We found decreased calcium and vitamin D levels, and increased phosphorus and ALP levels in OA patients compared to controls (P< 0.05).
Conclusion: Our results showed a negative correlation between melatonin and 8-OH-dG, as a DNA damage marker, in the serum of patients with OA. Decreased levels of melatonin and elevated levels of 8-OH-dG might play a role in the pathogenesis of OA. Taken together, our findings indicated that melatonin might be involved in decreasing DNA damage and exerting a preventive function in OA. Moreover, it can be a potentially useful therapeutic agent for patients with OA. However, this study was limited by application of a single analysis method to measure each laboratory parameter, a relatively small sample size, and lack of outcome data from the patients. Consequently, this study requires a larger sample size to validate prognostic and diagnostic values of these biomarkers. |